3.9 USD
-0.08 (-2.01%)
At close: Jan 30, 2026
3.9 USD
0 (0%)
Pre-Market: 2/2/2026, 7:08:20 AM
Taking everything into account, VYGR scores 2 out of 10 in our fundamental rating. VYGR was compared to 524 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for VYGR as it has an excellent financial health rating, but there are worries on the profitability. VYGR does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- In the past year VYGR has reported negative net income.
- In the past year VYGR has reported a negative cash flow from operations.
- In multiple years VYGR reported negative net income over the last 5 years.
- In the past 5 years VYGR reported 4 times negative operating cash flow.
1.2 Ratios
- The Return On Assets of VYGR (-43.75%) is comparable to the rest of the industry.
- Looking at the Return On Equity, with a value of -57.27%, VYGR is in the better half of the industry, outperforming 63.17% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -43.75% | ||
| ROE | -57.27% | ||
| ROIC | N/A |
ROA(3y)-2.68%
ROA(5y)-6.15%
ROE(3y)-14.79%
ROE(5y)-19.09%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- VYGR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- VYGR does not have a ROIC to compare to the WACC, probably because it is not profitable.
- VYGR has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for VYGR has been increased compared to 5 years ago.
- VYGR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- VYGR has an Altman-Z score of -0.85. This is a bad value and indicates that VYGR is not financially healthy and even has some risk of bankruptcy.
- VYGR's Altman-Z score of -0.85 is in line compared to the rest of the industry. VYGR outperforms 57.44% of its industry peers.
- VYGR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.85 |
ROIC/WACCN/A
WACC8.9%
2.3 Liquidity
- VYGR has a Current Ratio of 6.29. This indicates that VYGR is financially healthy and has no problem in meeting its short term obligations.
- VYGR has a Current ratio of 6.29. This is in the better half of the industry: VYGR outperforms 64.12% of its industry peers.
- A Quick Ratio of 6.29 indicates that VYGR has no problem at all paying its short term obligations.
- VYGR has a Quick ratio of 6.29. This is in the better half of the industry: VYGR outperforms 65.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.29 | ||
| Quick Ratio | 6.29 |
3. Growth
3.1 Past
- The earnings per share for VYGR have decreased strongly by -404.23% in the last year.
- The Revenue for VYGR has decreased by -80.88% in the past year. This is quite bad
- Measured over the past years, VYGR shows a decrease in Revenue. The Revenue has been decreasing by -5.18% on average per year.
EPS 1Y (TTM)-404.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-193.75%
Revenue 1Y (TTM)-80.88%
Revenue growth 3Y28.85%
Revenue growth 5Y-5.18%
Sales Q2Q%-45.73%
3.2 Future
- VYGR is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -6.88% yearly.
- The Revenue is expected to decrease by -8.25% on average over the next years.
EPS Next Y-88.71%
EPS Next 2Y-20.23%
EPS Next 3Y-8.07%
EPS Next 5Y-6.88%
Revenue Next Year-60.65%
Revenue Next 2Y-17.78%
Revenue Next 3Y-6.68%
Revenue Next 5Y-8.25%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for VYGR. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VYGR. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- VYGR's earnings are expected to decrease with -8.07% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.23%
EPS Next 3Y-8.07%
5. Dividend
5.1 Amount
- VYGR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
VOYAGER THERAPEUTICS INC / VYGR FAQ
What is the fundamental rating for VYGR stock?
ChartMill assigns a fundamental rating of 2 / 10 to VYGR.
What is the valuation status of VOYAGER THERAPEUTICS INC (VYGR) stock?
ChartMill assigns a valuation rating of 0 / 10 to VOYAGER THERAPEUTICS INC (VYGR). This can be considered as Overvalued.
What is the profitability of VYGR stock?
VOYAGER THERAPEUTICS INC (VYGR) has a profitability rating of 1 / 10.
Can you provide the financial health for VYGR stock?
The financial health rating of VOYAGER THERAPEUTICS INC (VYGR) is 7 / 10.
Can you provide the expected EPS growth for VYGR stock?
The Earnings per Share (EPS) of VOYAGER THERAPEUTICS INC (VYGR) is expected to decline by -88.71% in the next year.